XML 83 R55.htm IDEA: XBRL DOCUMENT
v3.25.4

Equity and Long-term Investments and Fair Value Measurements - Convertible Promissory Note in Syndeio Biosciences (Details) - USD ($) $ in Thousands |  |  |  |  |  |  |  |  |  | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Feb. 10, 2026 | Nov. 11, 2025 | Mar. 03, 2025 | Nov. 13, 2024 | Aug. 05, 2024 | Feb. 13, 2024 | Oct. 06, 2023 | Feb. 02, 2023 | Nov. 24, 2021 | Dec. 31, 2025 | Dec. 31, 2024 | Dec. 31, 2023
Equity Investment |  |  |  |  |  |  |  |  |  |  |  |
Additional cash investment |  |  |  |  |  |  |  |  |  | $ 17,500 | $ 0 | $ 1,218
Syndeio Biosciences |  |  |  |  |  |  |  |  |  |  |  |
Equity Investment |  |  |  |  |  |  |  |  |  |  |  |
Number of common stock issued description |  |  |  |  |  |  |  |  | The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the “Capped Conversion Price”) and the qualified event price (the “Qualified Event Price”). The Capped Conversion Price is calculated as $50.0 million divided by the number of shares of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Syndeio are at least $35.0 million, and (iii) the stated or implied equity valuation of Syndeio is at least $80.0 million. |  |  |
Syndeio Biosciences | Syndeio 2025 Convertible Note |  |  |  |  |  |  |  |  |  |  |  |
Equity Investment |  |  |  |  |  |  |  |  |  |  |  |
Equity and long-term investments at fair value |  |  |  |  |  |  |  |  |  | 24,500 |  |
Unrealized loss from fair value changes in equity investments |  |  |  |  |  |  |  |  |  | 1,300 |  |
Syndeio 2021 Convertible Note | Syndeio Biosciences |  |  |  |  |  |  |  |  |  |  |  |
Equity Investment |  |  |  |  |  |  |  |  |  |  |  |
Equity and long-term investments at fair value |  |  |  |  |  |  |  |  |  | 62,900 | 50,900 |
Unrealized gain from fair value changes in equity investments |  |  |  |  |  |  |  |  |  | $ 12,100 |  |
Unrealized loss from fair value changes in equity investments |  |  |  |  |  |  |  |  |  |  | $ 0 | $ 400
Convertible Promissory Note Purchase Agreement | Syndeio Biosciences |  |  |  |  |  |  |  |  |  |  |  |
Equity Investment |  |  |  |  |  |  |  |  |  |  |  |
Debt instrument maturity date |  |  | Nov. 24, 2026 |  |  |  |  |  |  |  |  |
Debt Instrument, Interest Rate, Effective Percentage |  |  | 8.00% |  |  |  |  |  | 8.00% |  |  |
Convertible notes face value |  | $ 25,800 | $ 15,000 |  | $ 39,800 | $ 33,500 | $ 27,700 | $ 21,500 | $ 15,000 |  |  |
Additional cash investment | $ 5,000 | $ 10,000 |  |  |  |  |  |  |  |  |  |
2021 Convertible Note | Syndeio Biosciences |  |  |  |  |  |  |  |  |  |  |  |
Equity Investment |  |  |  |  |  |  |  |  |  |  |  |
Convertible notes face value |  |  |  |  |  |  |  |  | $ 15,000 |  |  |
Convertible Promissory Note Purchase Agreement Amendment | Syndeio Biosciences |  |  |  |  |  |  |  |  |  |  |  |
Equity Investment |  |  |  |  |  |  |  |  |  |  |  |
Convertible notes face value |  |  |  |  |  |  |  | 21,500 |  |  |  |
Additional cash investment |  |  |  |  |  |  |  | $ 5,000 |  |  |  |
Convertible Promissory Note Purchase Agreement Second Amendment | Syndeio Biosciences |  |  |  |  |  |  |  |  |  |  |  |
Equity Investment |  |  |  |  |  |  |  |  |  |  |  |
Convertible notes face value |  |  |  |  |  |  | 27,700 |  |  |  |  |
Additional cash investment |  |  |  |  |  |  | $ 5,000 |  |  |  |  |
Convertible Promissory Note Purchase Agreement Third Amendment | Syndeio Biosciences |  |  |  |  |  |  |  |  |  |  |  |
Equity Investment |  |  |  |  |  |  |  |  |  |  |  |
Convertible notes face value |  |  |  |  |  | 33,500 |  |  |  |  |  |
Additional cash investment |  |  |  |  |  | $ 5,000 |  |  |  |  |  |
Convertible Promissory Note Purchase Agreement Fourth Amendment | Syndeio Biosciences |  |  |  |  |  |  |  |  |  |  |  |
Equity Investment |  |  |  |  |  |  |  |  |  |  |  |
Convertible notes face value |  |  |  |  | 39,800 |  |  |  |  |  |  |
Additional cash investment |  |  |  |  | $ 5,000 |  |  |  |  |  |  |
Convertible Promissory Note Purchase Agreement Fifth Amendment | Syndeio Biosciences |  |  |  |  |  |  |  |  |  |  |  |
Equity Investment |  |  |  |  |  |  |  |  |  |  |  |
Convertible notes face value |  |  |  | $ 50,600 |  |  |  |  |  |  |  |
Additional cash investment |  |  |  | $ 10,000 |  |  |  |  |  |  |  |
Convertible Promissory Note Purchase Agreement, Note Amendment Agreement | Syndeio Biosciences |  |  |  |  |  |  |  |  |  |  |  |
Equity Investment |  |  |  |  |  |  |  |  |  |  |  |
Convertible notes face value | $ 60,800 |  |  |  |  |  |  |  |  |  |  |

X
- Definition Number of common stock issued description. + References No definition available. + Details
Name: | inva_NumberOfCommonStockIssuedDescription
Namespace Prefix: | inva_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face (par) amount of debt instrument at time of issuance. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details
Name: | us-gaap_DebtInstrumentFaceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6 + Details
Name: | us-gaap_DebtInstrumentInterestRateEffectivePercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details
Name: | us-gaap_DebtInstrumentMaturityDate
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1 + Details
Name: | us-gaap_EquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details
Name: | us-gaap_EquitySecuritiesFvNiUnrealizedGain
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details
Name: | us-gaap_EquitySecuritiesFvNiUnrealizedLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 55 -Paragraph 10 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12 + Details
Name: | us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireLongtermInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=inva_SyndeioBiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |